Our offering
Alzheimer's Disease
Ncyte® Neural Mix or hiPSC-microglia
Parkinson's Disease
hiPSC-dopaminergic neurons
ALS / FTD
hiPSC-derived motor neurons
Neuroinflammation
Co-culture of hiPSC-derived neurons with astrocytes or microglia
Cardiac Hypertrophy
Ncyte® vCardiomyocytes
Gene Modulation
Cell model of your choice
Neurotoxicity
hiPSC-derived model of your choice
Cardiotoxicity
hiPSC-derived cardiomyocytes
Endothelial Barrier Function
Ncyte® Endothelial Cells
3D Cardiac Microtissues
Cardiac microtissues with hiPSC-derived ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts
3D Mature Neurospheres
Coming Soon
Alzheimer's Disease
| Readout | Technology |
|---|---|
| Phosphorylated TAU | High Content Imaging |
| MC-1 soluble TAU aggregates | |
| Insoluble TAU aggregates | |
| Proteasomal Activity | |
| Neurite growth | |
| Cytokine release | MSD, HTRF, ELISA |
| Electrophysiology | MEA |
Are you interested on this screening assay?
Request Screening AssayAre you looking for a custom solution?
Contact Us
Scientific poster: A human iPSC-based platform to screen therapeutics for ALS using specific and robust phenotypic assays covering disease relevant readouts.
Scientific poster: Development of a robust and scalable iPSC platform for predictions of efficacy and in vivo toxicity of RNA therapeutics in the drug discovery pipeline
Scientific poster: Development of robust iPSC-based a-Synuclein, TAU and TDP-43 aggregation models for drug discovery
Ready to start a conversation?
As more and more drug innovators look to capitalize on the unique value only iPSCs can deliver, they look to Ncardia as the uniquely qualified partner to join them on their all-important journeys.
Shushant Jain, PhD
Director of Discovery Technology
